Pharmacy Benefit Managers Accused by FTC of Prioritizing Profits Over Patient Well-being

FTC Accuses Pharmacy Benefit Managers of Prioritizing Profits Over Patients

The Federal Trade Commission (FTC) has escalated its efforts to address the rising concerns surrounding pharmacy benefit managers, alleging that their actions exacerbate high drug costs at the detriment of patients and independent pharmacies.

Impact on Patients and Independent Pharmacies

• The FTC accuses pharmacy benefit managers of prioritizing profits over patient well-being, potentially leading to increased drug costs.
• This practice may further strain patients' financial burdens and limit their access to essential medications.
• Independent pharmacies also face challenges due to these practices, potentially threatening their viability in the market.

Amidst the ongoing debate over healthcare affordability, the FTC's actions underscore the need for greater transparency and oversight in the pharmaceutical industry.